Management of Venous Thromboembolism in the Elderly

Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefit of thromboprophylaxis in medical patients. Thromb Haemost 2005 Oct; 94(4): 750–9 Kniffin Jr WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994 Apr 25; 154(8): 861–6 Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001 Jul; 86(1): 452–63 Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004 Nov 8; 164(20): 2260–5 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000 May; 83(5): 657–60 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000 Dec 11–25; 160(22): 3415–20 Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004 May 10; 164(9): 963–8 Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 2004 Aug; 52(8): 1299–304 Di Minno G, Mannucci PM, Tufano A, et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost 2005 Jul; 3(7): 1459–66 Bosson JL, Labarere J, Sevestre MA, et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: a multicenter cross-sectional study of risk factors, prophylaxis, and prevalence. Arch Intern Med 2003 Nov 24; 163(21): 2613–8 Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated hepa-rin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996 Oct; 76(4): 529–34 Tofler GH, Massaro J, Levy D, et al. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 2005 Nov 1; 96(9): 1280–3 Yamamoto K, Takeshita K, Kojima T, et al. Aging and plasmi-nogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardi-ovasc Res 2005 May 1; 66(2): 276–85 Di Minno G, Tufano A. Challenges in the prevention of venous thromboembolism in the elderly. J Thromb Haemost 2004 Aug; 2(8): 1292–8 Punukollu H, Khan IA, Punukollu G, et al. Acute pulmonary embolism in elderly: clinical characteristics and outcome. Int J Cardiol 2005 Mar 18; 99(2): 213–6 DeFrances CJ, Hall MJ. 2002 National Hospital Discharge Survey. Advance data from vital and health statistics; no. 342. Hyattsville (MD): National Center for Health Statistics, 2004 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad342.pdf [Accessed 2005 Dec] Heit JA, Sobell JL, Li H, et al. The incidence of venous thromboembolism among factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005 Feb; 3(2): 305–11 Wells PS, Langlois NJ, Webster MA, et al. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada: is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005 May; 93(5): 842–6 den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996 Mar 21; 334(12): 759–62 Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 Feb 9; 293(6): 715–22 DeFrances CJ, Hall MJ, Podgornik MN. 2003 National Hospital Discharge Survey. Advance data from vital and health statistics; no 359. Hyattsville (MD): National Center for Health Statistics, 2005 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad359.pdf [Accessed 2005 Dec] Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000 Mar 27; 160(6): 809–15 White RH, Zhou H, Gage BF. Effect of age on the incidence of venous thromboembolism after major surgery. J Thromb Haemost 2004 Aug; 2(8): 1327–33 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on An-tithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 338S–400S Chopard P, Dorffler-Melly J, Hess U, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 2005 Apr; 257(4): 352–7 Bratzler DW, Raskob GE, Murray CK, et al. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med 1998 Sep 28; 158(17): 1909–12 Aujesky D, Guignard E, Pannatier A, et al. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med 2002 Oct; 17(10): 788–91 Holley AB, Moores LK, Jackson JL. Provider preferences for DVT prophylaxis. Thromb Res, Epub 2005 May 14 Cabana MD, Rand CS, Powe NR, et al. Why donz’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999 Oct 20; 282(15): 1458–65 Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. Changing clinical practice: prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med 1994 Mar 28; 154(6): 669–77 Schunemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 688S–96S Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005 Mar 10; 352(10): 969–77 Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001 Apr; 38 (2 Suppl. 5): 12–9 Yale SH, Medlin SC, Liang H, et al. Risk assessment model for venothromboembolism in post-hospitalized patients. Int Angiol 2005 Sep; 24(3): 250–4 Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 401S–28S Arixtra prescribing information. Notre Dame: GlaxoS-mithKline, 2005 May [online]. Available from URL: http://www.arixtra.com [Accessed 2005 Dec] Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibri-nolysis 2003 Jun; 14(4): 341–6 Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16(2): 159–64 Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005 Feb 14; 165(3): 341–5 Aquino JP, Gambier A, Ducros J. Prevention of thromboembolic accidents in elderly subjects with fraxiparine. In: Bounameaux H, Samama MM, Ten Cate JW, editors. Fraxiparine, 2nd International Symposium: recent pharmacological and clinical data. Stuttgart, New York: Schattauer, 1990: 51–4 Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999 Sep 9; 341(11): 793–800 Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004 Aug 17; 110(7): 874–9 Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003 Apr; 145(4): 614–21 Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000 Jul 24; 160(14): 2199–207 Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162(16): 1833–40 Kolb G, Bodamer I, Galster H, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin certoparin after endoprosthetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003 Dec; 90(6): 1100–5 Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001 Mar; 83-A(3): 336–45 Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000 Jul 24; 160(14): 2208–15 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997 Aug; 84(8): 1099–103 Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002 Mar 28; 346(13): 975–80 Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000 Jan; 83(1): 14–9 Cohen AT, Davidson BL, Gallus AS, et al. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006 Feb 11; 332(7537): 325–9 Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001 Jul; 88(7): 913–30 Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005 Oct; 92(10): 1212–20 Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997 Mar; 79(3): 319–25 Fitzgerald Jr RH, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001 Jun; 83-A(6): 900–6 Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004 Jul; 2(7): 1058–70 Vormfelde SV. Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery [letter]. Lancet 2002; 360(9346): 1701 Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003 Aug 16; 362(9383): 504–5 Anderson Jr FA, Hirsh J, White K, et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest 2003 Dec; 124 (6 Suppl.): 349S–56S Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thrombopro-phylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002 Sep 23; 162(17): 1966–71 Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003 Jun 9; 163(11): 1337–42 Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003 Oct 30; 349(18): 1703–12 Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003 Dec; 1(12): 2490–6 Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003 Feb; 89(2): 288–96 Cohen AT, Hirst C, Sherrill B, et al. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg 2005 Nov; 92(11): 1335–44 Is that it, then, for blockbuster drugs? [editorial]. Lancet 2004 Sep 25-Oct 1; 364(9440): 1100 Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005 Dec 6; 46(11): 1986–95 Boos CJ, Lip GY. Ximelagatran: an eulogy. Thromb Res. Epub 2006 Apr 18 Longo MG, Greco A, Pacilli M, et al. Deep venous thrombosis in elderly hospitalized patients: prevalence and clinical features. Aging Clin Exp Res 2005 Feb; 17(1): 42–5 Siddique RM, Siddique MI, Connors Jr AF, et al. Thirty-day case-fatality rates for pulmonary embolism in the elderly. Arch Intern Med 1996 Nov 11; 156(20): 2343–7 Schutgens RE, Haas FJ, Biesma DH. Reduced efficacy of clinical probability score and D-dimer assay in elderly subjects suspected of having deep vein thrombosis. Br J Haematol 2005 Jun; 129(5): 653–7 Le Gal G, Righini M, Roy PM, et al. Differential value of risk factors and clinical signs for diagnosing pulmonary embolism according to age. J Thromb Haemost 2005 Nov; 3(11): 2457–64 Masotti L, Ceccarelli E, Cappelli R, et al. Pulmonary embolism in the elderly: clinical, instrumental and laboratory aspects. Gerontology 2000 Jul-Aug; 46(4): 205–11 Couturaud F, Parent F, Meyer G, et al. Effect of age on the performance of a diagnostic strategy based on clinical probability, spiral computed tomography and venous compression ultrasonography: the ESSEP study. Thromb Haemost 2005 Mar; 93(3): 605–9 Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001 Feb 6; 134(3): 191–202 Beckman JA, Dunn K, Sasahara AA, et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003 Jun; 89(6): 953–8 Findik S, Erkan ML, Selcuk MB, et al. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 2002; 69(5): 440–4 Prandoni P, Carnovali M, Marchiori A. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004 May 24; 164(10): 1077–83 Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs initial enoxaparin sodium followed by warfarin for a 180-day period. J Thromb Haemost 2003; 1Suppl. 1: OC194 Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003 Jul 10; 349(2): 146–53 Merli GJ. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment. J Thromb Thrombolysis 2004 Oct; 18(2): 117–25 Di Minno G, Tufano A, Cerbone AM. Antithrombotic drugs for older subjects: guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG). Nutr Metab Cardiovasc Dis 2001 Feb; 11(1): 41–62 Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004 Feb 3; 140(3): 175–83 Merli GJ. Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population. Clin Geriatr Med 2001 Feb; 17(1): 93–106 Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996 Mar 14; 334(11): 677–81 Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005 Apr 11; 165(7): 733–8 Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tas-man Study Group. N Engl J Med 1996 Mar 14; 334(11): 682–7 Chong BH, Brighton TA, Baker RI, et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005 Jun; 19(3): 173–81 Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002 Jul; 122(1): 108–14 Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000 Dec 11–25; 160(22): 3431–6 Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985 Sep 7; 2(8454): 515–8 Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995 Aug; 74(2): 606–11 Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000 Feb 28; 160(4): 470–8 Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003 Apr 10; 348(15): 1425–34 Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003 Aug 14; 349(7): 631–9 Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 204S–33S Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005 May 23; 165(10): 1095–106 van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993 Jul 12; 153(13): 1557–62 Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003 Sep; 1(9): 1906–13 Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002 Aug 12–26; 162(15): 1729–35 Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (ace-nocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000 Oct; 84(4): 559–64 Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy 2004 May; 24(5): 649–58 Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 Oct 30; 349(18): 1695–702 Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004 Jun 1; 140(11): 867–73 Schulman S, Wahlander Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003 Oct 30; 349(18): 1713–21 Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005 Feb 9; 293(6): 681–9 Zhan C, Correa-de-Araujo R, Bierman AS, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 2005 Feb; 53(2): 262–7 Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165(7): 784–9 Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38(1): 73–7 Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004 Jul 20; 141(2): 95–101 Epstein M. Aging and the kidney. J Am Soc Nephrol 1996 Aug; 7(8): 1106–22 Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003 Feb 10; 163(3): 356–60 Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998 Jun; 79(6): 1162–5 Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25(10): 725–33 Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000 Nov; 84(5): 800–4 Lovenox prescribing information. Bridgewater (NJ): Aventis Pharmaceuticals Inc., 2005 Nov [online]. Available from URL: http://www.lovenox.com [Accessed 2005 Dec] Fragmin prescribing information. New York: Pharmacia & Upjohn, 2004 Mar [online]. Available from URL: http://www.fragmin.com [Accessed 2005 Dec] Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 188S–203S Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005 Jun; 127(6): 2049–56 Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. Drugs Aging 1995 Jan; 6(1): 45–54 Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987 Apr; 82(4): 703–13 Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000 Nov; 84(5): 805–10 Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005 Jul 11; 165(13): 1527–32 Hutten BA, Lensing AW, Kraaijenhagen RA, et al. Safety of treatment with oral anticoagulants in the elderly: a systematic review. Drugs Aging 1999 Apr; 14(4): 303–12 Gasse Hollowell J, Meier CR, et al. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005 Sep; 94(3): 537–43 Campbell NR, Hull RD, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med 1996 Apr 22; 156(8): 857–60 American Geriatrics Society. Current guidelines for practice: oral anticoagulation for older adults. Pocket guide 2002 [online]. Available from URL: http://www.americangeriatrics.org [Accessed 2005 Dec]